anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In anticipation of the sequencing of the human genome and description of the human proteome, the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES) was initiated in 2002. AGES was designed to examine risk factors, including genetic susceptibility and gene/environment interaction, in relation to disease and disability in old age. The study is multidisciplinary, providing detailed phenotypes related to the cardiovascular, neurocognitive (including sensory), and musculoskeletal systems, and to body composition and metabolic regulation. Relevant quantitative traits, subclinical indicators of disease, and medical diagnoses are identified by using biomarkers, imaging, and other physiologic indicators. The AGES sample is drawn from an established population-based cohort, the Reykjavik Study. This cohort of men and women born between 1907 and 1935 has been followed in Iceland since 1967 by the Icelandic Heart Association. The AGES cohort, with cardiovascular risk factor assessments earlier in life and detailed late- life phenotypes of quantitative traits, will create a comprehensive study of aging nested in a relatively genetically homogeneous older population. This approach should facilitate identification of genetic factors that contribute to healthy aging as well as the chronic conditions common in old age.
The invention provides an application of CC motif chemokine receptor 1 in preparing a biomarker for detecting breast cancer lung metastasis or breast cancer poor prognosis. The invention also provides application of the reagent for detecting the CC motif chemokine receptor 1 in preparing a kit for detecting breast cancer lung metastasis or breast cancer poor prognosis. The invention provides application of CC motif chemokine receptor 1 as a target spot in screening drugs for inhibiting breast cancer or breast cancer lung metastasis. The invention provides application of a CC motif chemokine receptor 1 antagonist in preparing a medicament for inhibiting breast cancer or breast cancer lung metastasis. The present invention finds that CCR1 is abnormally highly expressed in breast cancer metastasis and metastatic breast cancer cell lines compared to breast cancer in situ foci and less metastatic breast cancer cell lines. In vivo animal experiments have shown that it promotes metastasis in situ tumors, while the use of CCR1 antagonists can inhibit the occurrence of such metastasis.
BACKGROUND AND AIMS: The atherogenic index of plasma (AIP) is associated with progression of atherosclerosis and used to describe how pro- or anti-atherogenic components are balanced. However, the association of AIP with asymptomatic intracranial arterial stenosis (aICAS) is uncertain. The purpose of this study is to investigate the association between AIP and aICAS in rural China.
METHODS AND RESULTS: A total of 1990 participants aged ≥40 years free of stroke or transient ischemic attack were enrolled in this study. The presence of aICAS was examined by Transcranial Doppler ultrasound and confirmed by magnetic resonance angiography. The adjusted AIP (aAIP) was calculated according to the ratio of TG and HDL-C and further separated into 4 quartiles. Multiple logistic regression was used to investigate the association between aAIP and aICAS, and the dose-response relationship was explored by restricted cubic spline. After adjusting for conventional confounders, aAIP was significantly higher in the aICAS group than that in the non-aICAS group. Furthermore, the common odds ratios for aICAS risk increased with increasing aAIP quartiles. Multivariate logistic regression revealed that aAIP was independently associated with aICAS in female or middle-aged and elderly (age ≥50 years), and superior to other lipid profiles. Multiple-adjusted spline regression showed the dose-response association between aAIP levels and aICAS prevalence.
CONCLUSIONS: AIP might be independently and positively associated with the prevalence of aICAS in middle-aged and elderly women, which might be superior to traditional and nontraditional lipid profiles in rural China.
The purpose of this study is to determine the effects of palm oil on blood lipids, cardiovascular health and inflammation. Potential subjects will be screened until 24 qualifying healthy participants are enrolled. After enrollment participants will undergo a baseline battery of tests including blood draws, body composition, measures of height and weight, blood lipid profile (cholesterol, lipoprotein particle size, quantity and fatty acid composition), insulin sensitivity using a static index, inflammation, antioxidant status and measurement of energy expenditure and substrate oxidation by indirect calorimetry. Participants will be randomly divided into one of two arms/tracks, either a low carbohydrate diet arm or a high carbohydrate diet arm. Each diet arm consists of 3 phases a low saturated fat control diet where the primary cooking oil is canola oil and two saturated fat diet phases where the primary cooking oil is either palm oil or butter.

Participants will begin with the low saturated fat diet phase first which consists of 50% of fat calories derived from canola oil for 3 weeks. At the end of this control diet phase the battery of tests completed at baseline will be repeated. After a 2-week washout period participants will then proceed in random order into either the palm oil or butter diet phases of their diet arm/track. The palm oil and butter diet phases are also 3 weeks in duration and separated by a 2 week washout period. The palm oil and butter diet phases will derive 50% of the fat calories from either palm oil or butter. Both oils are high in saturated fat but differ in the quality of saturated fat. At the end of each diet phase the testing battery completed at baseline will be repeated. The subjects will never be exposed to more than minimal risk and in return will receive 9 weeks of food, individualized reports of their study results and a monetary stipend. The study will help us better understand how the quality of saturated fat and the quantity of carbohydrate interact to impact blood lipids and cardiovascular health. This knowledge can be used to aid dietary recommendations for cardiovascular health and control of blood lipids.
The primary objective of this study is to evaluate under double blind conditions the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an open label and long term maintenance treatment on extended release Equetro in children and adolescents aged 10-17 year diagnosed with acute manic or mixed bipolar I disorder. The safety evaluations will be based on the occurrence of treatment-emergent adverse events, laboratory values, physical examination, vital signs ECG and trough serum level of study medication. The secondary objective is to evaluate under double blind conditions the efficacy of extended release Equetro versus placebo followed by an open label and long term maintenance treatment on extended release Equetro in children and Adolescents Aged 10-17 years diagnosed with acute manic or mixed Bipolar I disorder. Efficacy evaluations will be based on the measures of YMRS, CGI-S, CGI-I, CDRS-R. Manic episodes over double blind and open label periods will comprise the use of study medication and duration of night time sleep as monitored using a daily diary. Subject's will be enrolled in the double blind period for two months and evaluated on a weekly basis. Once completing the db phase they will continue on Equetro for long term maintenance for an additional six months. Placebo subject will have the opportunity to continue for another eight months in the study. The first two months will be the titration period as was done in the db phase and then they will have the option to continue in the study for an open long term maintenance for and additional 6 months. During the maintenance period subjects will be evaluated for safety and efficacy on a monthly basis. At the end of the study there will be a 30 day follow-up.
Disclosed herein are systems and methods for monitoring and evaluating neuromodulation therapy. A system configured in accordance with embodiments of the present technology may include, for example, a guidewire having a proximal portion, a distal portion configured to be positioned at a target site in a vessel of a human patient, and a sensing element positioned along the distal portion. The sensing element may be a pressure sensing element, a flow sensing element, an impedance sensing element, and/or a temperature sensing element. The system may also include a controller configured to obtain one or more measurements related to a physiological parameter of the patient via the sensing element. Based on the measured values, the controller may determine a physiological parameter and compare the parameter to a predetermined threshold. Based on the comparison, the controller and/or operator may assess the likelihood that the patient will benefit from neuromodulation therapy.
The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17????-hydroxysteroid dehydrogenase type I (17????-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17????-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17????-estradiol concentration.
Trithorax-related H3K4 methyltransferases, KMT2C and KMT2D, are critical epigenetic modifiers. Haploinsufficiency of KMT2C was only recently recognized as a cause of neurodevelopmental disorder (NDD), so the clinical and molecular spectrums of the KMT2C-related NDD (now designated as Kleefstra syndrome 2) are largely unknown. We ascertained 98 individuals with rare KMT2C variants, including 75 with protein-truncating variants (PTVs). Notably, ∼15% of KMT2C PTVs were inherited. Although the most highly expressed KMT2C transcript consists of only the last four exons, pathogenic PTVs were found in almost all the exons of this large gene. KMT2C variant interpretation can be challenging due to segmental duplications and clonal hematopoesis-induced artifacts. Using samples from 27 affected individuals, divided into discovery and validation cohorts, we generated a moderate strength disorder-specific KMT2C DNA methylation (DNAm) signature and demonstrate its utility in classifying non-truncating variants. Based on 81 individuals with pathogenic/likely pathogenic variants, we demonstrate that the KMT2C-related NDD is characterized by developmental delay, intellectual disability, behavioral and psychiatric problems, hypotonia, seizures, short stature, and other comorbidities. The facial module of PhenoScore, applied to photographs of 34 affected individuals, reveals that the KMT2C-related facial gestalt is significantly different from the general NDD population. Finally, using PhenoScore and DNAm signatures, we demonstrate that the KMT2C-related NDD is clinically and epigenetically distinct from Kleefstra and Kabuki syndromes. Overall, we define the clinical features, molecular spectrum, and DNAm signature of the KMT2C-related NDD and demonstrate they are distinct from Kleefstra and Kabuki syndromes highlighting the need to rename this condition.
This is comprised of a growth mindset module (2 sessions), a gratitude module (1 session) and a value affirmations module (1 session). Sessions are delivered weekly (over 4 weeks) and each session lasts for an hour. Reading and writing activities and group discussions are included in each session. Participants are supposed to complete homework exercises are assigned between sessions.
FIELD: medicine.SUBSTANCE: group of inventions can be used to produce a medicinal agent based on a liposome composition for treating a condition associated with inflammation. Liposome contains a lipid ingredient and encapsulates the bisphosphonate. Liposome has weight ratio of said bisphosphonate to lipid ingredient from 1:5 to 1:8. Lipid ingredient contains distearoyl phosphatidyl choline (DSPC), distearoyl phosphatidyl glycerol (DSPG) and cholesterol in molar ratio of 3:1:2. Liposome has compressibility value less than 0.70 ml/g. Invention also discloses a liposome, a composition of liposomes and use of a formulation for preparing a medicinal agent.EFFECT: group of inventions enables to obtain a homogeneous and stable liposomal composition for treating a condition associated with inflammation.15 cl, 6 tbl, 5 dwg, 4 ex
FIELD: organic chemistry, heterocyclic compounds, pharmacy. SUBSTANCE: invention relates to the novel acyl derivatives of guanosine of the formula (I)  , inosine of the formula (II)  , xanthosine of the formula (III)  , deoxyinosine of the formula (IV)  , deoxyguanosine of the formula (V)  , inosine-2', 3'-(acyclic)-dialcohol of the formula (VI)   or their pharmaceutically acceptable salts. Values of radicals R A ,R B ,R C ,R D , Y, Q and Z are given in corresponding points of the invention claim. Invention describes a pharmaceutical composition stimulating hemopoiesis and containing derivatives of guanosine or inosine or their salts as an active agent. Invention proposes also method of treatment of animals with cytopenia by administration of indicated compounds in effective doses. Invention can be used in medicinal practice and therapy in hemopoiesis disorders. EFFECT: compounds indicated above, valuable medicinal properties. 17 cl, 68 dwg, 53 ex
Over the past decade, there has been an alarming trend toward earlier breast development in girls. The contemporaneous obesity epidemic has led to speculation that obesity may be driving early puberty. However, questions remain about the validity of reports of early puberty among obese girls due to the difficulty in distinguishing fatty tissue from breast tissue in this population. The physiological basis for early puberty among obese girls is also unknown. The current proposal aims to investigate pubertal development in pre-menarchal obese compared with normal weight girls using more robust methods such as breast morphological staging via ultrasonography and intensive reproductive axis phenotyping. Study procedures include blood draws, DXA (for body composition), hand x-ray (for bone age), breast and transabdominal (pelvic) ultrasounds, and anthropometrics.
OBJECTIVE: Migraine, a prevalent and debilitating disease, involves complex pathophysiology possibly including inflammation and heightened pain sensitivity. The current study utilized the complete Freund's adjuvant (CFA) model of inflammation, with onabotulinumtoxinA (BoNT/A) as a treatment of interest due to its use in clinical migraine management. Using an animal model, the study sought to investigate the role of BoNT/A in modulating CFA-induced inflammation, alterations in pain sensitivity, and the regulation of calcitonin gene-related peptide (CGRP) release. Further, we aimed to assess the changes in SNAP-25 through western blot analysis to gain insights into the mechanistic action of BoNT/A.
METHODS: BoNT/A or control was administered subcutaneously at the periorbital region of rats 3 days before the induction of inflammation using CFA. Periorbital mechanical sensitivity was assessed post-inflammation, and alterations in CGRP release were evaluated. Changes in SNAP-25 levels were determined using western blot analysis.
RESULTS: Upon CFA-induced inflammation, there was a marked increase in periorbital mechanical sensitivity, with the inflammation side showing increased sensitivity compared to other periorbital areas. BoNT/A did decrease the withdrawal thresholds in the electronic von Frey test. Despite not being able to observe differences in pain thresholds or CGRP release, BoNT/A reduced baseline release under CFA inflamed conditions. Analysis of SNAP-25 levels in the trigeminal ganglion revealed both intact and cleaved forms that were notably elevated in BoNT/A-treated animals. These findings, derived from western blot analysis, suggest an effect on neurotransmitter release.
CONCLUSION: Our investigation highlights the role of BoNT/A in reducing baseline CGRP in the context of inflammation and its involvement in SNAP-25 cleavage. In contrast, BoNT/A did not appear to alter facial pain sensitivity induced by inflammation, suggesting that mechanisms other than baseline CGRP could be implicated in the elevated thresholds in the CFA model.
OBJECTIVES: This study focused on the serology, clinical characteristics, and hemolytic potential of warm reactive autoantibodies detected by solid phase red cell adherence.
METHODS: Ninety-seven patients with warm autoantibodies were evaluated. Serologic characteristics included the strength of solid phase reactivity, the results of tube-based ancillary testing, direct antiglobulin test and eluate results, and an assessment for contemporaneous alloantibodies. Clinical characteristics of the patients included age, sex, and primary diagnosis. Each patient was also assessed for evidence of hemolysis.
RESULTS: Most of the 97 study patients were female (63.9%), and the average age was 66 years. Hematologic disorders were the most common diagnosis. A majority (70.1%) of the warm autoantibodies had 3 to 4+ reaction strengths, and approximately 90% had negative testing with at least 1 test tube method. There was an even distribution of direct antiglobulin test reaction strengths, with 74% reactive with anti-immunoglobulin G only. Alloantibodies were identified in 20% of patients. Evidence of hemolysis was identified in only 13 patients (13.4%).
CONCLUSIONS: Warm reactive autoantibodies are more likely to be hemolytic, have strongly reactive indirect and direct antiglobulin tests, remain reactive in tube-based ancillary testing methods, and are seen primarily in patients with hematologic disorders.
The invention discloses a reptile-derived antibacterial peptide Alligatorin5, an amino acid sequence thereof and applications of the antibacterial peptide in the antibacterial field. The antibacterial peptide Alligatorin5 is derived from Chinese alligator. By searching a Chinese alligator gene database, screening and analyzing, a mature peptide sequence of the antibacterial peptide is obtained. The amino acid sequence of the antibacterial peptide Alligatorin5 is shown as SEQ ID NO.1 in a sequence table. By comparative analysis, the antibacterial peptide Alligatorin5 is obviously different from amino acid sequences of antibacterial peptides known at present, and belongs to a novel antibacterial pepetide. Antibacterial experiments show that: the antibacterial peptide Alligatorin5 has high antibacterial activity for gram positive bacteria, gram negative bacteria and funguses, and is broad in antibacterial spectrum and efficient; the antibacterial peptide Alligatorin5 has characteristics of low hemolytic activity, salt tolerance, heat tolerance, good thermal stability, and the like, and can be used for the fields of medicines, cosmetics, food fresh-keeping and the breeding industry.
AIM: This study aimed to assess the feasibility and effectiveness of the pectoral nerves (PECS) II block in facilitating cardiac implantable electronic device (CIED) insertion in a sample of 120 patients, with a focus on the percentage of cases completed without additional intraoperative local anesthesia.
METHODS: PECS II blocks were performed on the left side using ultrasound guidance in all 120 patients. Feasibility was assessed by the proportion of cases completed without the need for extra intraoperative local anesthetic. Secondary outcomes included the amount of additional local anesthetic used, intraoperative opioid requirements, postoperative pain scores, time to first postoperative analgesia, analgesic consumption, patient satisfaction, and block-related complications.
RESULTS: Of the 120 patients, 78 (65%) required additional intraoperative local anesthetic, with a median volume of 8.2 mL (range 3-13 mL). Fifteen patients (12.5%) needed intraoperative opioid supplementation. Nine patients (7.5%) required postoperative tramadol for pain relief. In total, 98 patients (81.7%) reported high satisfaction levels with the procedure.
CONCLUSIONS: The PECS II block, when combined with supplementary local anesthetic, provided effective postoperative analgesia for at least 24 h in 120 patients undergoing CIED insertion. While it did not completely replace surgical anesthesia in most cases, the PECS II block significantly contributed to a smoother intraoperative experience for patients.
Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
An application of red algae polysaccharide as ceramide expression promoter and its preparation method are provided. The molecular weight of the red algae polysaccharide is less than or equal to 100kDa. The rhodophyta polysaccharide can induce the expression of main enzymes involved in the anabolic pathway of the ceramide, thereby increasing the activity of the related enzymes and achieving the effect of improving the content of the ceramide in cells. Therefore, the cosmetic or the skin external medicine with the ceramide regulation effect prepared by using the rhodophyta polysaccharide is smeared on the skin, and can promote the skin barrier repair and inhibit the expression of inflammatory factors in the skin. The preparation method of the red algae polysaccharide utilizes the subcritical extraction combined with the enzymatic hydrolysis treatment process, and can accurately control the molecular weight of the obtained red algae polysaccharide. Compared with the traditional hot water extraction or subcritical extraction process, the preparation method can improve the extraction rate of the rhodophyta polysaccharide, can prepare the rhodophyta polysaccharide with the molecular weight less than or equal to 100kDa, and can improve the heavy metal removal rate of the rhodophyta polysaccharide.
Participants will receive standard occupational therapy with no TECH protocol. or Will receive active standard care: six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.